Explainer: Why U.S. hospitals see promise in plasma from new coronavirus
patients
Send a link to a friend
[April 04, 2020]
By Deena Beasley
(Reuters) - U.S. hospitals desperate to
help very sick patients with COVID-19, the highly contagious respiratory
disease caused by the new coronavirus, are trying a treatment first used
in the 1890s that relies on blood plasma donated by recovered patients.
People who survive an infectious disease like COVID-19 are generally
left with blood containing antibodies, or proteins made by the body's
immune system to fight off a virus. The blood component that carries the
antibodies can be collected and given to newly infected patients - it is
known as "convalescent plasma."
More than a million Americans have tested positive for COVID-19, and
epidemiologists say hundreds of thousands more likely have the disease.
To help match donors to hospitals, the AABB, formerly the American
Association of Blood Banks, this week issued guidelines on plasma
collection. The American Red Cross also launched an online registry for
potential donors.
The U.S. Food and Drug Administration on Friday announced an "expanded
access" program for convalescent plasma, coordinated by the Mayo Clinic
in Rochester, Minnesota, aimed at making it easier for hospitals across
the country to collect and use plasma.
IS THERE EVIDENCE THIS WILL WORK?
"Historically, this has worked," said Dr. Jeffrey Henderson, associate
professor of medicine and molecular microbiology at Washington
University School of Medicine in St. Louis. “Before we had vaccines,
this was used for infectious diseases like measles and diphtheria."
Convalescent plasma was also successfully used during the 1918 flu
pandemic, he said.
Doctors say protocols, such as dosage, are still uncertain for COVID-19
patients, but they believe the method is worth trying, at least until an
effective COVID-19 vaccine or treatment is developed.
The Mayo Clinic and other U.S. sites are conducting a clinical study.
Similar trials are under way in other countries where the virus has hit
and some data has begun to emerge.
In one trial in China, levels of the virus in five seriously ill
COVID-19 patients were undetectable after plasma transfusions, according
to study results published last week in The Journal of the American
Medical Association.
[to top of second column]
|
HOW IS PLASMA BEING TRIED?
The process involves drawing blood from a donor - in this case
someone who has recovered from COVID-19 but is in generally good
health and meets other criteria for blood donation - and running it
through a machine to extract the plasma. The remaining blood goes
back into the donor.
The process takes up to 90 minutes, and plasma from a single donor
can be used to treat three or four patients.
Donors must have been diagnosed with COVID-19 and need to wait a
defined period of time after they test negative for the disease
before donating plasma. Tests are also being developed to measure
antibody volume.
Centers including Houston Methodist Hospital and several hospitals
in hard-hit New York City have used the experimental treatment on an
emergency basis for patients who are seriously ill with COVID-19.
Dr. Timothy Byun, a hematologist/oncologist at St. Joseph Hospital
in Orange, California, dosed his first COVID-19 patient on
Wednesday. He said the patient was doing better, but it was too
early to tell if the therapy was effective.
St. Joseph, a 450-bed hospital, does not have a blood donation
center and instead had to modify a dialysis machine to collect
plasma from the donor.
Before the plasma infusion, Byun's patient had received multiple
treatments, including the malaria drug hydroxychloroquine and the
intravenous anti-inflammatory drug Actemra, but his condition still
worsened.
Risks of the plasma therapy could include infusion site reactions or
other rare, allergic reactions.
"Of the current therapeutic options, I believe convalescent plasma
offers the best chance of efficacy in treatment," said Dr. Daniel
McQuillen, an infectious disease specialist at Lahey Hospital &
Medical Center in Burlington, Massachusetts.
(Reporting by Deena Beasley; Editing by Leslie Adler)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |